防喘合剂加辅舒酮吸入治疗轻度持续性哮喘患儿的临床观察

Clinical Observation on Treatment of Children's Mild Continuous Asthma by Fangchuan Mixture Combined with Flixotide

目的观察自拟防喘合剂对轻度持续性哮喘患儿的疗效。方法将175例患儿分为3组,分别给予防喘合剂(中药组,62例)、辅舒酮(西药组,48例)吸入及两药合用(联合组,65例)治疗,共治疗12周;观察3组患儿治疗后哮喘控制情况、中医证候缓解情况、呼气峰流速,并且测定血清免疫球蛋白、细胞因子(IL-4、IFN-γ)含量。结果3组各项指标治疗后均明显好转(P<0.05),3组间比较,无日间哮喘无数比例、合用β2受体激动剂的天数,咯痰、面色不华、纳差症状改善情况和IFN-γ水平升高,联合组均优于中药组和西药组(P<0.05),多汗、脉细弱改善情况、IL-4下降水平联合组和中药组优于西药组(P<0.05);鼻塞喷嚏改善情况联合组优于西药组(P<0.05);其余指标3组比较差异无统计学意义。结论防喘合剂可以减轻患儿气道变应性炎症,改善过敏状态,并且与辅舒酮有协同作用。

Objective To investigate the efficacy and mechanism of Fangchuan Mixture （FCM） in treating children with mild continuous asthma. Methods One hundred and seventy-five patients in the three groups were treated with FCM （A）, Flixotide （B）, and the combination of FCM and Flixotide （C）, respectively for 12 weeks. Their condition of asthma and TCM syndrome were observed, peak expiratory flow （PEF） and serum levels of immunoglobulin （Ig）, interleukin-4 （IL-4） and interferon-7 （IFN-7） were determined. Results All the indexes determined were improved significantly in the three groups after treatment （P 〈 0.05）. Paired com- parison among groups showed that the improvements in non-asthma time, time required B-receptor activator, ex- pectoration, complexion, appetite, and increasing serum IFN-7 after treatment were superior in Group C than in Group A and B （P 〈 0.05） ; the improvements in hidrosis, faint pulse and decreasing serum IL-4 level in Group A and C were better than those in Group B （P 〈 0.05）, and the effect for alleviating symptoms of rhinitis such as nasal obstruction and nasal discharge in Group C was more significant than that in Group B （P 〈 0.05）. Con- clusion FCM could attenuate the allergic inflammation of bronchi to improve its hypersensitive state in children with asthma, and shows a cooperative action with Flixotide.